{"id":"bx-1","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3916849","moleculeType":"Small molecule","molecularWeight":"471.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BX-1 is a phytopharmaceutical product developed by Bionorica SE, typically composed of standardized plant extracts. The mechanism involves modulation of innate immune responses and reduction of inflammatory mediators relevant to respiratory conditions. Bionorica's products generally work through multiple bioactive compounds that enhance mucosal immunity and reduce airway inflammation.","oneSentence":"BX-1 is a herbal extract combination that modulates immune and inflammatory pathways to support respiratory and immune function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:17.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory tract infections or related respiratory conditions (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT04448808","phase":"PHASE2","title":"Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-10-01","conditions":"Posttraumatic Stress Disorder","enrollment":170},{"nctId":"NCT03984214","phase":"PHASE3","title":"Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-12-16","conditions":"Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic","enrollment":109},{"nctId":"NCT03756974","phase":"PHASE3","title":"BX-1 in Spasticity Due to Multiple Sclerosis","status":"COMPLETED","sponsor":"Bionorica SE","startDate":"2019-02-18","conditions":"Spasticity Due to Multiple Sclerosis","enrollment":397}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BX-1","genericName":"BX-1","companyName":"Bionorica SE","companyId":"bionorica-se","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BX-1 is a herbal extract combination that modulates immune and inflammatory pathways to support respiratory and immune function. Used for Respiratory tract infections or related respiratory conditions (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}